MMP-13 is constitutively produced in human chondrocytes and co-endocytosed with ADAMTS-5 and TIMP-3 by the endocytic receptor LRP1
Matrix metalloproteinase 13 (MMP-13) degrades collagenous extracellular matrix and its aberrant activity associates with diseases such as arthritis, cancer, atherosclerosis and fibrosis. The wide range of MMP-13 proteolytic capacity suggests that it is a powerful, potentially destructive proteinase...
Main Authors: | Yamamoto, K, Okano, H, Miyagawa, W, Visse, R, Shitomi, Y, Santamaria, S, Dudhia, J, Troeberg, L, Strickland, D, Hirohata, S, Nagase, H |
---|---|
Format: | Journal article |
Published: |
Elsevier
2016
|
Similar Items
-
Low density lipoprotein receptor-related protein 1 (LRP1)-mediated endocytic clearance of a disintegrin and metalloproteinase with thrombospondin motifs-4 (ADAMTS-4): functional differences of non-catalytic domains of ADAMTS-4 and ADAMTS-5 in LRP1 binding.
by: Yamamoto, K, et al.
Published: (2014) -
Investigation of the endocytic pathway of ADAMTS-4
by: Owen, K, et al.
Published: (2009) -
LRP-dependent and -independent internalisation of TIMP-3
by: Scilabra, S, et al.
Published: (2011) -
Cellular uptake of proMMP-2:TIMP-2 complexes by the endocytic receptor megalin/LRP-2
by: Manuel Johanns, et al.
Published: (2017-06-01) -
Endocytic pathways of TIMP-3 and its N-terminal inhibitory domain
by: Scilabra, S, et al.
Published: (2009)